Neurodevelopmental and genetic findings in neonates with intracranial arteriovenous shunts: A case series.
arteriovenous malformation
brain injury
neurodevelopmental disorders
patient outcome assessment
vascular malformations
vein of galen malformations
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
11
2022
accepted:
15
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Despite the latest advances in prenatal diagnosis and postnatal embolization procedures, intracranial arteriovenous shunts (AVSs) are still associated with high mortality and morbidity rates. Our aim was to evaluate the presentation and clinical course, the neurodevelopmental outcome, and the genetic findings of neonates with AVSs. In this retrospective observational study, medical records of neonates with cerebral AVSs admitted to our hospital from January 2020 to July 2022 were revised. In particular, we evaluated neuroimaging characteristics, endovascular treatment, neurophysiological features, neurodevelopmental outcomes, and genetic findings. We described the characteristics of 11 patients with AVSs. Ten infants (90.9%) required embolization during the first three months of life. In 5/9 infants, pathological electroencephalography findings were observed; of them, two patients presented seizures. Eight patients performed Median Nerve Somatosensory Evoked Potentials (MN-SEPs): of them, six had an impaired response. We found normal responses at Visual Evoked Potentials and Brainstem Auditory Evoked Potentials. Eight patients survived (72.7%) and were enrolled in our multidisciplinary follow-up program. Of them, 7/8 completed the Bayley-III Scales at 6 months of corrected age: none of them had cognitive and language delays; conversely, a patient had a moderate delay on the Motor scale. The remaining survivor patient developed cerebral palsy and could not undergo Bayley-III evaluation because of the severe psychomotor delay. From the genetic point of view, we found a novel pathogenic variant in the NOTCH3 gene and three additional genomic defects of uncertain pathogenicity. We propose SEPs as an ancillary test to discern the most vulnerable infants at the bedside, particularly to identify possible future motor impairment in follow-up. The early identification of a cognitive or motor delay is critical to intervene with personalized rehabilitation treatment and minimize future impairment promptly. Furthermore, the correct interpretation of identified genetic variants could provide useful information, but further studies are needed to investigate the role of these variants in the pathogenesis of AVSs.
Sections du résumé
Background
UNASSIGNED
Despite the latest advances in prenatal diagnosis and postnatal embolization procedures, intracranial arteriovenous shunts (AVSs) are still associated with high mortality and morbidity rates. Our aim was to evaluate the presentation and clinical course, the neurodevelopmental outcome, and the genetic findings of neonates with AVSs.
Methods
UNASSIGNED
In this retrospective observational study, medical records of neonates with cerebral AVSs admitted to our hospital from January 2020 to July 2022 were revised. In particular, we evaluated neuroimaging characteristics, endovascular treatment, neurophysiological features, neurodevelopmental outcomes, and genetic findings.
Results
UNASSIGNED
We described the characteristics of 11 patients with AVSs. Ten infants (90.9%) required embolization during the first three months of life. In 5/9 infants, pathological electroencephalography findings were observed; of them, two patients presented seizures. Eight patients performed Median Nerve Somatosensory Evoked Potentials (MN-SEPs): of them, six had an impaired response. We found normal responses at Visual Evoked Potentials and Brainstem Auditory Evoked Potentials. Eight patients survived (72.7%) and were enrolled in our multidisciplinary follow-up program. Of them, 7/8 completed the Bayley-III Scales at 6 months of corrected age: none of them had cognitive and language delays; conversely, a patient had a moderate delay on the Motor scale. The remaining survivor patient developed cerebral palsy and could not undergo Bayley-III evaluation because of the severe psychomotor delay. From the genetic point of view, we found a novel pathogenic variant in the NOTCH3 gene and three additional genomic defects of uncertain pathogenicity.
Conclusion
UNASSIGNED
We propose SEPs as an ancillary test to discern the most vulnerable infants at the bedside, particularly to identify possible future motor impairment in follow-up. The early identification of a cognitive or motor delay is critical to intervene with personalized rehabilitation treatment and minimize future impairment promptly. Furthermore, the correct interpretation of identified genetic variants could provide useful information, but further studies are needed to investigate the role of these variants in the pathogenesis of AVSs.
Identifiants
pubmed: 37063679
doi: 10.3389/fped.2023.1111527
pmc: PMC10090511
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1111527Informations de copyright
© 2023 Campi, De Rose, Pugnaloni, Ronci, Calì, Pro, Longo, Lucignani, Raho, Pisaneschi, Digilio, Savarese, Bersani, Amante, Conti, De Liso, Capolupo, Braguglia, Gandolfo and Dotta.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Neurosurg Pediatr. 2018 Apr;21(4):367-374
pubmed: 29350590
J Matern Fetal Neonatal Med. 2022 Dec;35(25):5312-5317
pubmed: 33508985
Ultrasound Obstet Gynecol. 2017 Aug;50(2):192-199
pubmed: 27514305
Respir Res. 2022 Jan 11;23(1):6
pubmed: 35016680
Neuroimaging Clin N Am. 2013 Nov;23(4):757-70
pubmed: 24156863
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5643-8
pubmed: 11344305
AJNR Am J Neuroradiol. 2020 Dec;41(12):2370-2376
pubmed: 33093132
Pediatr Neurol. 2022 Jun;131:25-29
pubmed: 35462109
Am J Obstet Gynecol. 2020 Dec;223(6):B27-B29
pubmed: 33168212
Development. 2001 Oct;128(19):3675-83
pubmed: 11585794
Front Pediatr. 2022 Sep 30;10:976060
pubmed: 36245731
J Pediatr Surg. 2015 Mar;50(3):394-8
pubmed: 25746695
Circ Res. 2004 Apr 16;94(7):910-7
pubmed: 14988227
Arch Dis Child. 2019 Nov;104(11):1064-1069
pubmed: 31122925
Clin Neurophysiol. 2021 Apr;132(4):886-903
pubmed: 33684728
Clin Neurophysiol. 2018 Jan;129(1):95-100
pubmed: 29172116
J Cell Mol Med. 2015 Aug;19(8):1986-93
pubmed: 25846406
Brain. 2018 Apr 1;141(4):979-988
pubmed: 29444212
Sci Rep. 2015 Nov 13;5:16449
pubmed: 26563570
J Clin Invest. 2000 Mar;105(5):597-605
pubmed: 10712431
Minerva Pediatr (Torino). 2021 Apr 02;:
pubmed: 33820408
Eur J Pediatr. 2022 Apr;181(4):1609-1618
pubmed: 35066625
Genes Dev. 2004 Nov 15;18(22):2730-5
pubmed: 15545631
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10901-6
pubmed: 18667694
Radiol Case Rep. 2021 Oct 21;16(12):3961-3964
pubmed: 34745403
AJNR Am J Neuroradiol. 2017 Dec;38(12):2308-2314
pubmed: 28982789